Oracle (NYSE: ORCL) and AstraZeneca announced a partnership to advance AI-enabled healthcare solutions focused on real-world data and clinical research. The collaboration aims to improve identification of eligible patients for clinical trials and to speed up evidence generation from real-world datasets. Both companies plan to link research outputs directly into care delivery workflows across several therapeutic areas, including chronic and complex diseases. The Oracle and AstraZeneca AI-enabled healthcare partnership is a material shift that investors may want to weigh against other findings. Check out 3 warning signs (1 major) that Oracle investors should know about.
Главную мысль мы показываем публично. Создайте бесплатный аккаунт, чтобы читать статью полностью, сохранять ее, обсуждать и связывать с рынками и OSINT-контекстом.